The news: Novo Nordisk’s shares fell about 10% on Friday amid disappointing results for a late-stage anti-inflammatory drug (ziltivekimab) being tested as a cardiovascular treatment. The experimental drug did not produce a statistically significant reduction in major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal heart attack or non-fatal stroke. Two additional trials testing the drug are expected in H1 next year.

Why it matters: While Novo is not a major cardiovascular drugmaker like Bristol Myers Squibb, AstraZeneca, Bayer, Novartis, or Amgen, it has strong incentives to test areas beyond GLP-1s, which account for roughly three-quarters of its revenues. Although Novo remains the No. 2 GLP-1 player and oral Wegovy has shown promising early momentum, the obesity market will soon become more competitive. Expanding into adjacent therapeutic areas (like cardiovascular) could help offset growing pricing and competitive pressure while reducing dependence on GLP-1s.

Novo’s CEO Mike Doustdar said earlier this year that the company would like to move into drug categories beyond obesity and diabetes. While Doustdar didn't specifically mention expanding into cardiovascular drugs at that time, the category represents one of pharma's largest markets, as heart disease remains the leading cause of death worldwide.

Implications for pharma: For Novo, the cardiovascular trial setback could increase pressure to look at growth strategies beyond just internal development, potentially using its deep pockets to access externally developed drug candidates with validated clinical potential. Novo's chief scientific officer said the setback doesn't change its commitment to cardiovascular disease, but investors have less reason to expect a near-term win from that program now.

For drugmakers broadly, smaller biotechs with credible pipeline assets should continue attracting acquisition interest as Big Pharma opens its wallets at a much faster pace than last year. Meanwhile, Novo's diversification push reinforces the value of building multiple growth engines, which could further support M&A activity as large drugmakers look to broaden their therapeutic portfolios.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.